Editor’s highlights from Future Oncology – March 2021

Written by Louis Gautier, Future Science Group

Future Oncology February issue

In this latest instalment of his regular monthly column, Louis Gautier, Commissioning Editor of Future Oncology, exclusively shares some of his top picks from the recent journal issues, which we have made freely available for you, Oncology Central members! Check out Louis’ highlights below: The patient’s perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050 The ARCHER 1050 trial begun in 2013 and aimed to compare dacomitinib (Vizimpro®) with gefitinib (Iressa®) in 452 patients with locally advanced or metastatic EGFR+ NSCLC. The most recent update of the trial (median follow-up of 47.9 months) showed that patients...

To view this content, please register now for access

It's completely free